67 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
of PATHFNDR-2 are incredibly exciting for both patients with acromegaly and the healthcare providers who treat them,” stated Monica R. Gadelha, M.D., Ph.D
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist
8-K
EX-99.1
kckkrc0os
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
lbiww
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
3m5gqq0s
11 Sep 23
Regulation FD Disclosure
6:05am
UPLOAD
kh6r3by1xl2xw835o
20 Dec 22
Letter from SEC
12:00am
8-K
EX-99.1
wc2zgrup 1z5
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
h1dfdidx
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
424B5
bsz bkar5m0w1as8o
13 Apr 22
Prospectus supplement for primary offering
4:22pm